Elimination Game Begins for Innovative Pharma Firms (AI Translation)
Listen to the full version
文｜财新周刊 滑昂
By Caixin Weekly's Hua Ang
股市爆发式行情，创新药板块同样跟涨。
The stock market is experiencing explosive growth, with the innovative pharmaceutical sector following suit.
港股市场中，创新药板块沉寂已久。中证香港创新药指数（931787.CSI）在过往的2021年初至今年8月底，累计下跌约54%，已被认为是超跌。而在9月，该指数强势上涨25.8%，尤其在当月下旬拉升最为明显。多只聚焦在港股创新药的交易型开放式指数基金（ETF）亦走出类似上涨趋势。
In the Hong Kong stock market, the innovative drug sector has long been dormant. The China Securities Hong Kong Innovative Drug Index (931787.CSI) plummeted approximately 54% from early 2021 to the end of August this year, leading many to consider it oversold. However, in September, the index surged by 25.8%, with a significant rise particularly noticeable in the latter part of the month. Several exchange-traded funds (ETFs) focusing on innovative drugs in the Hong Kong stock market also exhibited similar upward trends.
内地市场，国庆假期前A股初现行情。10月8日上证指数涨停开盘报3674点，更令一众投资者惊叹。中证创新药产业指数（931152.CSI）在9月最后5个交易日的涨幅达到28%，10月8日单日上涨9.11%。
In the mainland market, a rally emerged in A-shares right before the National Day holiday. The Shanghai Composite Index opened with an impressive uptick on October 8, closing at 3,674 points, much to the surprise of many investors. The CSI Innovative Pharmaceutical Industry Index (931152.CSI) surged 28% over the last five trading days of September and rose 9.11% on October 8 alone.
- DIGEST HUB
Digest Hub
Back
- The pharmaceutical sector in the Hong Kong and mainland markets saw a resurgence, with indices rising significantly in September and early October, reflecting renewed optimism.
- Companies like BeiGene and Innovent Biologics approached break-even due to product sales growth, but financial challenges and strategic shifts persist for many firms.
- Cross-border licensing and the NewCo model are new trends in the sector, as companies adapt to financial pressures and the evolving market landscape.
[para. 1] The stock market is experiencing significant growth, notably within the innovative pharmaceutical sector. The Hong Kong stock market's innovative drug segment, represented by the China Securities Hong Kong Innovative Drug Index, declined by about 54% from early 2021 to August 2023 but saw a resurgence with a 25.8% increase in September, bolstered by strong performances in specific ETFs.
[para. 2] Similarly, the mainland stock market saw a rally, particularly in A-shares before the National Day holiday. The CSI Innovative Pharmaceutical Industry Index rose by 28% in the closing days of September and gained 9.11% on October 8, signaling robust investor activity.
[para. 3] Factors contributing to this increase include the U.S. Federal Reserve's interest rate cuts and China's supportive financial policies. However, market volatility persists due to differing investor reactions and emerging "penny stocks."
[para. 5] Notably, Akeso Inc. experienced fluctuations with its stock dropping after initial disappointing data on Ivonescimab, only to rebound by almost 40% after positive Phase 3 trial results against Merck’s Pembrolizumab for lung cancer were announced.
[para. 6] Akeso's success story continued as they presented favorable data at the World Conference on Lung Cancer, marking an important challenge to Merck's position. This news drove Akeso’s stocks up by 15.77% in a single day.
[para. 8] Investors remain cautious as internal financial challenges, such as cash flow issues and fundraising difficulties, linger. Notably, companies like Sinovent and RemeGen face liquidity problems despite significant R&D investments.
[para. 9] Sector-wide, leading pharmaceutical companies like BeiGene and Innovent Biologics are nearing break-even thanks to better product commercialization. However, overall healthcare financing has slowed, illustrated by a decrease in both the number and value of primary market financings in China.
[para. 10] Mergers and acquisitions indicate a trend, with companies like JHBP entering reverse takeovers, signifying strategic shifts in the sector's landscape as they strive to leverage synergies in R&D and commercialization strengths.
[para. 11] Innovative pharmaceutical firms are leaning towards efficiency, with cost-cutting, strategic staff reductions, and asset streamlining becoming common practices to weather volatility. Notably, industry stalwarts like RemeGen, initially successful for its ADC therapy, are revisiting their business strategies due to cash constraints and evolving market conditions.
[para. 12] The industry is experiencing structural shifts driven by the necessity to sustain operations while exploring new revenue streams. Companies are adopting innovative practices, like the "NewCo model," to propel global partnerships and faster drug commercialization.
[para. 14] Acknowledging global trends, domestic drug firms aim to bolster local markets as foundations for growth, particularly following the inclusion of innovative drugs in healthcare coverage, which promises increased market penetration domestically.
[para. 15] Lastly, investors are keeping an eye on secondary market valuations, which influence primary market dynamics. Opportunities arise as firms restructure for greater efficiencies, reflecting the converging trends of volatility and strategic resilience within the innovative pharmaceutical sector.
- Akeso, Inc.
康方生物 - Akeso, Inc. (康方生物) experienced a significant stock price fluctuation in May after its core product, Ivonescimab, received approval in China but was initially perceived to have underwhelming clinical data. Following a positive outcome in a head-to-head Phase 3 trial against Merck's Keytruda, its stock price recovered nearly 40%. In September, Akeso's stock rose 15.77% based on updated clinical data presented at the 2024 World Lung Cancer Conference.
- Merck & Co.
默沙东 - The article mentions Merck & Co. in the context of competition with Akeso Inc., whose drug penpulimab presented a strong challenge to Merck's Keytruda in a phase 3 trial for PD-L1 positive non-small cell lung cancer. The trial showed significant improvement in progression-free survival compared to Keytruda.
- Summit Therapeutics
Summit Therapeutics - Summit Therapeutics, an American company with no commercialized products in its pipeline, benefitted from acquiring rights to Akeso's Ivuxolimab. This acquisition has created substantial value for the company, with its market value approaching $25 billion in mid-September 2023, putting it on par with China-based BeiGene, which is well-known to Chinese investors.
- BeiGene
百济神州 - BeiGene, a leading biopharma company, achieved total revenue of 11.996 billion yuan in the first half of 2023, a 65.4% year-on-year increase. The company's net loss attributable to the parent company was 2.877 billion yuan, reduced by approximately 2.342 billion yuan year-on-year. Its main products, BTK inhibitor Zanubrutinib and PD-1 antibody Tislelizumab, generated sales totaling 10.2 billion yuan, which constituted around 85% of the company's total revenue.
- Innovent Biologics
信达生物 - Innovent Biologics, highlighted in the article, has experienced significant growth, with first half total revenue reaching 39.52 billion yuan, a 46.3% increase. Its core product, PD-1 inhibitor sintilimab, generated approximately 17 billion yuan in sales during the first six months, growing by 45.6%. The company aims for 200 billion yuan in sales in the Chinese market by 2027 and plans to achieve EBITDA break-even by 2025 as part of its financial goals.
- Henlius
复宏汉霖 - Henlius (复宏汉霖) achieved profitability earlier through product sales in the first half of the year, reversing its previous losses. The company is highlighted in the context of innovation and commercialization within the Chinese innovative drug sector.
- Athenex
艾力斯 - The article does not mention Athenex. It focuses on the recent fluctuations and trends in the innovative drug sector in the Hong Kong and mainland China stock markets, highlighting company performances, investment strategies, and financial challenges faced by companies like Akeso and Rongchang Biopharmaceuticals. The report also discusses market dynamics, capital challenges, and strategic adjustments within the sector.
- Betta Pharmaceuticals
百利天恒 - Betta Pharmaceuticals, known as China's "first innovative drug stock," has been actively cutting costs, especially in R&D. As of mid-2024, the company had reduced its number of PhD employees. While not directly stating layoffs, it's evident that the company is minimizing expenses. Despite this, specific details about their workforce and R&D downsizing remain somewhat guarded.
- Ascentage Pharma
亚盛医药 - Ascentage Pharma (06855.HK) is mentioned as one of the companies that monetized their pipeline assets, receiving significant upfront payments, which helped them achieve a turnaround in profitability in the first half of the year.
- Bio-Thera Solutions
科伦博泰 - The article does not mention Bio-Thera Solutions. It focuses on the innovation drug sector in the Hong Kong market, detailing trends, companies like BeiGene, Innovent Biologics, and recent challenges and opportunities within the industry. If you need specific information about Bio-Thera Solutions, it would be necessary to consult other sources not provided in this article.
- Sinovac Biotech
圣诺医药 - The article does not provide specific details about Sinovac Biotech. It focuses on the performance and challenges of the innovative drug sector, highlighting companies like BeiGene, Innovent Biologics, and others within the context of market dynamics and financial challenges.
- RemeGen
荣昌生物 - RemeGen, known for developing various antibody drugs, faces liquidity issues despite raising over 6 billion RMB from two IPOs. The company rapidly consumed cash due to heavy R&D investments, and earlier this year, rumors of a potential financial crisis led to a stock price plunge. Although management denied the crisis, they have acknowledged efforts to shrink R&D and reduce costs, including layoffs. RemeGen's stock price and investor confidence remain sensitive to market rumors.
- InnoCare
诺诚健华 - InnoCare (Nocera) has cash reserves exceeding 40 billion yuan, as of the end of June. Despite this, like other companies in the innovative drug sector, it faces challenges with tightened capital exit channels and a slowed financing pace within the domestic healthcare industry.
- Zai Lab
再鼎医药 - The article mentions that Zai Lab (09688.HK) is among the innovation-driven pharmaceutical companies with significant monetary funds, exceeding 40 billion yuan, as of mid-year 2023. However, it notes that their monetary funds have declined compared to the end of 2022.
- CANbridge Pharmaceuticals
北海康成 - The article does not mention CANbridge Pharmaceuticals. The focus is on the broader context of the innovative drug sector in Hong Kong and mainland China's stock markets, including trends, key players, and challenges within the industry, without specific details about CANbridge Pharmaceuticals.
- Kintor Pharmaceutical
开拓药业 - Kintor Pharmaceutical faced challenges during the COVID-19 pandemic, investing in clinical trials for Proxalutamide's potential as a COVID-19 treatment. Despite previous market optimism, results fell short. Another setback came with the failure of a clinical trial for their hair loss drug last year. As of mid-2023, Kintor had available cash of approximately 334 million yuan and unused bank financing of 80 million yuan, reducing its net loss to 71.5 million yuan by controlling expenses.
- CStone Pharmaceuticals
基石药业 - CStone Pharmaceuticals, founded in 2015, is a biotech company that initially attracted significant investment and was listed on the Hong Kong Stock Exchange in 2019. It adopted a strategy of self-research and licensing for rapid product commercialization. Facing financial pressures, the company has recently reduced staff and operational costs, sold assets, and achieved its first profitability in the first half of the year after cutting expenses by approximately 230 million yuan.
- Betta Pharmaceuticals
贝达药业 - Betta Pharmaceuticals, dubbed China's "first innovative drug stock," is reducing costs and focusing on cash reserves. As of mid-2023, it has nearly 50 PhD holders and a reduction in R&D personnel by 13.14% since the end of 2022. The company has not directly disclosed employee reductions but is cutting R&D expenses. Despite its stature, it faces pressure to streamline operations amidst industry challenges.
- Genor Biopharma
嘉和生物 - Genor Biopharma, founded in 2007, focuses on innovative and biosimilar drug pipelines in solid tumors and hematologic cancers. It went public on the Hong Kong Stock Exchange in October 2020, raising approximately HKD 2.694 billion. Despite having only one approved infliximab biosimilar and facing challenges with its core PD-1 antibody project, the company reported a loss of HKD 132 million in the first half of the year. Its latest market value is under HKD 1 billion.
- Jiangsu Hengrui Medicine
恒瑞医药 - Jiangsu Hengrui Medicine licensed its GLP-1 drug combination, excluding the Greater China area, to the newly formed U.S.-based Hercules company for a transaction total potentially reaching $60 billion. The deal included a $100 million upfront payment. Hengrui received a 19.9% stake in Hercules, which was founded with a $400 million investment by multiple funds, such as Bain Capital Life Sciences Fund and Atlas Ventures.
- Connect Biopharma
康诺亚 - The article does not mention Connect Biopharma specifically. It focuses on the overall trends and challenges facing the innovative drug industry in Hong Kong and China, highlighting companies like BeiGene, Innovent Biologics, and others, as well as discussing issues like financial challenges, market dynamics, and development strategies within the innovation-driven pharmaceutical sector.
- Eton Pharmaceuticals
亿腾医药 - The article mentions that Eton Pharmaceuticals was merged with Genor Biopharma in a reverse acquisition to form a new company, "Eton Genor," after multiple attempts to IPO in Hong Kong. Eton Pharmaceuticals initially focused on contract sales but recently pursued innovation, resulting in significant annual revenue and profits from anti-infective, cardiovascular, and respiratory products.
- PODCAST
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新